{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:01:06Z","timestamp":1791216066212,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1016\/j.neuropharm.2003.09.005","type":"journal-article","created":{"date-parts":[[2003,10,30]],"date-time":"2003-10-30T05:48:19Z","timestamp":1067492899000},"page":"254-263","source":"Crossref","is-referenced-by-count":205,"title":["Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats"],"prefix":"10.1016","volume":"46","author":[{"given":"Dorit Ben","family":"Shachar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nava","family":"Kahana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Kampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Warshawsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussa B.H","family":"Youdim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2003.09.005_BIB1","first-page":"L23","article-title":"Melatonin is protective against MPTP-induced striatal and hippocampal lesions","volume":"60","author":"Acuna-Castroviejo","year":"1997","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0736-5748(86)90019-5","article-title":"Long-term consequence of early iron-deficiency on dopaminergic neurotransmission in rats","volume":"4","author":"Ben-Shachar","year":"1986","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB3","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/j.1471-4159.1991.tb06358.x","article-title":"Iron-melanin interaction and lipid peroxidation: implications for Parkinson\u2019s disease","volume":"57","author":"Ben-Shachar","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB4","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/j.1471-4159.1991.tb11444.x","article-title":"The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons","volume":"56","author":"Ben-Shachar","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB5","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0301-5629(99)00046-0","article-title":"Iron accumulation in the substantia nigra in rats visualized by ultrasound","volume":"25","author":"Berg","year":"1999","journal-title":"Ultrasound Med. Biol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB6","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/bi992296v","article-title":"Interaction between 6-hydroxydopamine and transferrin: \u201cLet my iron go\u201d","volume":"39","author":"Borisenko","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0006-8993(89)91530-8","article-title":"Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence","volume":"476","author":"Cadet","year":"1989","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/clinchem\/9.2.188","article-title":"Marco and Micro method for the determination of serum iron and iron binding capacity","author":"Caraway","year":"1963","journal-title":"Clin. Chem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1749-6632.2000.tb06180.x","article-title":"Oxidative stress, mitochondrial respiration and Parkinson\u2019s disease","volume":"899","author":"Cohen","year":"2000","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB10","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/j.1471-4159.1989.tb07264.x","article-title":"Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson\u2019s disease","volume":"52","author":"Dexter","year":"1989","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.1989.tb09133.x","article-title":"Basal lipid peroxidation in substantia nigra is increased in Parkinson\u2019s disease","volume":"52","author":"Dexter","year":"1989","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB12","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1046\/j.1471-4159.1998.70062492.x","article-title":"In vitro studies of ferritin iron release and neurotoxicity","volume":"70","author":"Double","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1146\/annurev.nutr.20.1.627","article-title":"Iron regulatory proteins and the molecular control of mammalian iron metabolism","volume":"20","author":"Eisenstein","year":"2000","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0014-2999(98)00696-7","article-title":"Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo","volume":"360","author":"Ferger","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/mds.870130208","article-title":"Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine","volume":"13","author":"Gassen","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0014-2999(96)00291-9","article-title":"Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction","volume":"308","author":"Gassen","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1471-4159.1994.63030793.x","article-title":"Altered brain metabolism of iron as a cause of neurodegenerative diseases?","volume":"793","author":"Gerlach","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB18","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1046\/j.1471-4159.1996.66052004.x","article-title":"Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine","volume":"66","author":"Glinka","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0014-2999(98)00279-9","article-title":"Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine","volume":"351","author":"Glinka","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB20","first-page":"329","article-title":"Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine","volume":"292","author":"Glinka","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0006-8993(96)00284-3","article-title":"An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys","volume":"724","author":"Goto","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB22","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/1531-8257(199907)14:4<612::AID-MDS1010>3.0.CO;2-6","article-title":"Apomorphine protects against MPTP-induced neurotoxicity in mice","volume":"14","author":"Grunblatt","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.2001.00397.x","article-title":"Gene expression analysis in MPTP mice model of Parkinson\u2019s disease using cDNA microarray","volume":"78","author":"Grunblatt","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1046\/j.1471-4159.2001.t01-1-00227.x","article-title":"Effects of R-apomorphine and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss","volume":"77","author":"Grunblatt","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0022-510X(92)90247-I","article-title":"MRI, brain iron and experimental Parkinson\u2019s disease","volume":"113","author":"Hall","year":"1992","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1471-4159.1958.tb12607.x","article-title":"The effect of age on the nonhaem iron in the human brain","author":"Hallgren","year":"1958","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2165\/00002512-200118090-00004","article-title":"Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment","volume":"18","author":"Halliwell","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB28","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1046\/j.1471-4159.1999.731683.x","article-title":"Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson\u2019s disease","volume":"73","author":"Han","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB29","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1073\/pnas.94.14.7531","article-title":"Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson\u2019s disease","volume":"94","author":"Hunot","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB30","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1248\/cpb.36.3387","article-title":"Synthesis of 2,3-dihydro-1,4-benzodioxin derivatives. I. 2-substituted- 5(and 6)-sulfamoyl-2,3-dihydro-1,4-benzodioxins","volume":"36","author":"Itazaki","year":"1988","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/BF02252926","article-title":"Brain iron and ferritin in Parkinson\u2019s and Alzheimer\u2019s diseases","volume":"2","author":"Jellinger","year":"1990","journal-title":"J. Neural. Transm. Park Dis. Dement. Sect."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB32","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/j.1471-4159.1992.tb08362.x","article-title":"Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis","volume":"59","author":"Jellinger","year":"1992","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00002512-199914020-00004","article-title":"The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson\u2019s disease","volume":"14","author":"Jellinger","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB34","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1212\/WNL.47.6_Suppl_3.161S","article-title":"Oxidative stress and the pathogenesis of Parkinson\u2019s disease","volume":"47","author":"Jenner","year":"1996","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neuropharm.2003.09.005_BIB35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0896-6273(03)00126-0","article-title":"Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson\u2019s disease","volume":"37","author":"Kaur","year":"2003","journal-title":"Neuron 27"},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB36","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF01277665","article-title":"Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice","volume":"104","author":"Lan","year":"1997","journal-title":"J. Neural. Transm. (Budapest)"},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB37","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/BF01291883","article-title":"Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson\u2019s disease","volume":"104","author":"Lan","year":"1997","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB38","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1212\/WNL.47.6_Suppl_3.153S","article-title":"The etiology of Parkinson\u2019s disease with emphasis on the MPTP story","volume":"47","author":"Langston","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/84859","article-title":"Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice","volume":"27","author":"LaVaute","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s004180000246","article-title":"Immunolocalization of iron regulatory protein expression in the murine central nervous system","volume":"115","author":"Leibold","year":"2001","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB41","unstructured":"Levenson, C.W., Perkov B. and Matteson A., 2003. Effect of dietary iron deficiency on motor behaviour and neuronal death in an experimental model of Parkinsoism. Journal of American Aging Association, (in press)."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0006-2952(01)00813-9","article-title":"Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures","volume":"63","author":"Levites","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB43","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1046\/j.1471-4159.2001.00490.x","article-title":"Green tea polyphenol (\u2212)- Epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration","volume":"78","author":"Levites","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB44","first-page":"G1355","article-title":"Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages","volume":"272","author":"Lin","year":"1997","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1124\/mol.52.3.465","article-title":"(\u2212)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB","volume":"52","author":"Lin","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0925-4439(96)00020-8","article-title":"Dopamine, 6-hydroxydopamine, iron, and dioxygen-\u2014their mutual interactions and possible implication in the development of Parkinson\u2019s disease","volume":"1316","author":"Linert","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/10715769009109678","article-title":"Release of iron from ferritin by 6-hydroxydopamine under aerobic and anaerobic conditions","volume":"11","author":"Lode","year":"1990","journal-title":"Free Radic. Res. Commun."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB48","first-page":"123","article-title":"Genes and oxidative stress in parkinsonism; cDNA microarray studies","volume":"91","author":"Mandel","year":"2003","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0014-4886(91)90086-R","article-title":"Distribution and number of transferrin receptors in Parkinson\u2019s disease and in MPTP-treated mice","volume":"114","author":"Mash","year":"1991","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB50","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ana.410410318","article-title":"Use of desferrioxamine in the treatment of aceruloplasminemia","volume":"41","author":"Miyajima","year":"1997","journal-title":"Annal. Neurol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB51","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0304-3940(94)90462-6","article-title":"Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys","volume":"168","author":"Mochizuki","year":"1994","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB52","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1016\/0006-2952(89)90512-1","article-title":"6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation","volume":"38","author":"Monteiro","year":"1989","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/exnr.2000.7516","article-title":"The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson\u2019s disease","volume":"166","author":"Moussaoui","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB54","first-page":"143","article-title":"Cytokines in Parkinson\u2019s disease","volume":"58","author":"Nagatsu","year":"2002","journal-title":"J. Neural. Transm. Suppl."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0006-8993(94)90833-8","article-title":"Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study","volume":"660","author":"Oestreicher","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB56","series-title":"The rat brain in stereotaxic coordinates","author":"Paxinos","year":"1982"},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3940(85)90229-0","article-title":"Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse","volume":"60","author":"Perry","year":"1985","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB58","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1021\/jm970099t","article-title":"Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson\u2019s disease","volume":"40","author":"Pezzella","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB59","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0003-9861(87)90531-5","article-title":"The inhibition site of MPP+, the neurotoxic bioactivation product of 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase","volume":"259","author":"Ramsay","year":"1987","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB60","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/j.1471-4159.1980.tb11254.x","article-title":"Peroxidative changes in brain cortical fatty acids and phospholipids, as characterized during Fe2+- and ascorbic acid-stimulated lipid peroxidation in vitro","volume":"34","author":"Rehncrona","year":"1980","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB61","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1471-4159.1989.tb09150.x","article-title":"Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains","volume":"52","author":"Riederer","year":"1989","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB62","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0006-8993(00)03296-0","article-title":"Neuroprotective effect of vitamin E on the early model of Parkinson\u2019s disease in rat: behavioral and histochemical evidence","volume":"892","author":"Roghani","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB63","first-page":"110","article-title":"Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors","volume":"777","author":"Seaton","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB64","first-page":"743","article-title":"Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases","volume":"46","author":"Shoham","year":"2000","journal-title":"Cell Mol. Biol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB65","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF01244786","article-title":"Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain","volume":"74","author":"Sofic","year":"1988","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB66","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1471-4159.1994.62010134.x","article-title":"Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis","volume":"62","author":"Temlett","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB67","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1248\/cpb.34.682","article-title":"Studies on positive inotropic agents. II. Synthesis of (4-substituted 1- piperazinylcarbonyl)-2-(1H)-quinolinone derivatives","volume":"34","author":"Tominaga","year":"1986","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB68","first-page":"G1240","article-title":"Iron primes hepatic macrophages for NF-kappaB activation in alcoholic liver injury","volume":"277","author":"Tsukamoto","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB69","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-2999(68)90164-7","article-title":"6-Hydroxy-dopamine induced degeneration of central monoamine neurons","volume":"5","author":"Ungerstedt","year":"1968","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB70","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1471-4159.1970.tb02210.x","article-title":"Effects of 6-hydroxydopamine on catecholamine containing neurones in the rat brain","volume":"17","author":"Uretsky","year":"1970","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB71","unstructured":"Warshawsky, B., Ben-Shachar, D., Youdim, M.B.H., 2000. Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators. International application published under the patent cooperationtreaty. International Publication Number WO 00\/74664 A2."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB72","first-page":"1","article-title":"Storage iron in man","volume":"177","author":"Weinfeld","year":"1964","journal-title":"Acta Medica Scandinavia Suppl."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mds.870080102","article-title":"The possible role of iron in the etiopathology of Parkinson\u2019s disease","volume":"8","author":"Youdim","year":"1993","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB74","doi-asserted-by":"crossref","unstructured":"Youdim, M.B.H., 1985. Brain iron metabolism. biochemical and behavioral aspects in relation to dopaminergic neurotransmission. In: Handbook of Neurochemistry. Plenum, New York.","DOI":"10.1007\/978-1-4757-0797-7_27"},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB75","unstructured":"Youdim, M.B.H., Riederer, P., 2003. Iron in the brain, normal and pathological.conditions. In: Smith, B., Adelman, G. (Eds.), Encyclopedia of Neuroscience. Elsevier, Amsterdam (in press)."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1749-6632.1999.tb07977.x","article-title":"The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson\u2019s disease with iron chelators","volume":"890","author":"Youdim","year":"1999","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.neuropharm.2003.09.005_BIB77","doi-asserted-by":"crossref","unstructured":"Youdim, M.B.H., Eshel, G., Ben-Shachar D., 2003. Ironing out iron from Parkinson\u2019s disease and other neurodegenerative diseases with iron chelators; A lesson from 6-hydroxydopamine and iron chelators desferal and VK-28. Ann. NY Acad. Sci. (In press).","DOI":"10.1196\/annals.1306.025"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839080300354X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839080300354X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T06:01:34Z","timestamp":1704952894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839080300354X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S002839080300354X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2003.09.005","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}